Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT05594797
Recruiting
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Phase 2 · China · 2 sites
Registry update: 9 Dec 2022
NCT05722405
Recruiting
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Phase 4 · China · 1 site
Registry update: 5 Jan 2026
NCT06250595
Recruiting
European Rare Blood Disorders Platform (ENROL)
Not applicable · Spain · 1 site
Registry update: 9 Feb 2024
NCT05312255
Recruiting
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Not applicable · United States · 1 site
Registry update: 9 Nov 2026
NCT05053607
Recruiting
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab
Not applicable · United States · 2 sites
Registry update: 11 Dec 2024
NCT05055063
Recruiting
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
Phase 1 · United States · 1 site
Registry update: 11 Jun 2026
NCT07087964
Recruiting
Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients
Not applicable · Belgium · 4 sites
Registry update: 28 Jul 2025
NCT05135351
Recruiting
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy
Not applicable · United States · 1 site
Registry update: 27 Jul 2026
NCT04771572
Recruiting
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Phase 1 · United States · 8 sites
Registry update: 5 May 2026
NCT04657861
Recruiting
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
Early phase 1 · China · 1 site
Registry update: 9 May 2022
NCT05366881
Recruiting
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Not applicable · United States · 17 sites
Registry update: 4 Nov 2026
NCT05294055
Recruiting
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Phase 2 · China · 7 sites
Registry update: 13 May 2025
NCT05203003
Recruiting
Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.
Not applicable · France · 1 site
Registry update: 6 Dec 2024
NCT04795882
Recruiting
A New Study Evaluating the Activity of Modular CAR T for mYeloma
Phase 1 · United Kingdom · 1 site
Registry update: 20 Nov 2025
NCT04211259
Recruiting
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
Early phase 1 · United States · 2 sites
Registry update: 29 May 2026
NCT05361694
Recruiting
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
Not applicable · United States · 1 site
Registry update: 9 Apr 2026
NCT05219721
Recruiting
A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Phase 1 · China · 1 site
Registry update: 11 Jun 2025
NCT05201781
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Phase 4 · Belgium, China, Germany, Spain, France, Israel, Japan, Netherlands, Sweden, United States · 64 sites
Registry update: 3 Nov 2026
NCT04988555
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/2 · Belgium, Canada, Switzerland, Spain, France, United Kingdom, Italy, Japan, South Korea, Singapore, Taiwan, United States · 104 sites
Registry update: 24 Mar 2026
NCT05145400
Recruiting
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Phase 2 · United States · 5 sites
Registry update: 2 Jun 2026

Ordered by registry start date. Freshness and sponsorship never change the order.